247 related articles for article (PubMed ID: 24052463)
1. Erythropoietin use in CKD patients with cancer: to tread with caution?
Nayak-Rao S; McCormick B
J Nephrol; 2013; 26(5):829-35. PubMed ID: 24052463
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin biology in cancer.
Hardee ME; Arcasoy MO; Blackwell KL; Kirkpatrick JP; Dewhirst MW
Clin Cancer Res; 2006 Jan; 12(2):332-9. PubMed ID: 16428469
[TBL] [Abstract][Full Text] [Related]
3. Treatment with erythropoiesis-stimulating agents in chronic kidney disease patients with cancer.
Hazzan AD; Shah HH; Hong S; Sakhiya V; Wanchoo R; Fishbane S
Kidney Int; 2014 Jul; 86(1):34-9. PubMed ID: 24402094
[TBL] [Abstract][Full Text] [Related]
4. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression.
Hedley BD; Allan AL; Xenocostas A
Clin Cancer Res; 2011 Oct; 17(20):6373-80. PubMed ID: 21750199
[TBL] [Abstract][Full Text] [Related]
5. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents.
Tanaka T; Nangaku M
Exp Cell Res; 2012 May; 318(9):1068-73. PubMed ID: 22414872
[TBL] [Abstract][Full Text] [Related]
6. Recombinant Erythropoietin Provides Protection against Renal Fibrosis in Adenine-Induced Chronic Kidney Disease.
Vázquez-Méndez E; Gutiérrez-Mercado Y; Mendieta-Condado E; Gálvez-Gastélum FJ; Esquivel-Solís H; Sánchez-Toscano Y; Morales-Martínez C; Canales-Aguirre AA; Márquez-Aguirre AL
Mediators Inflamm; 2020; 2020():8937657. PubMed ID: 32184703
[TBL] [Abstract][Full Text] [Related]
7. Forewarned is forearmed: erythropoietin use in CKD patients with cancer.
Kessler SJ; Bennett CL
J Nephrol; 2013; 26(5):805-6. PubMed ID: 24052466
[TBL] [Abstract][Full Text] [Related]
8. Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.
Rainville N; Jachimowicz E; Wojchowski DM
Expert Opin Ther Targets; 2016; 20(3):287-301. PubMed ID: 26419263
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin in cancer: the new face of an old friend.
Megalakaki C
J BUON; 2008; 13(1):7-16. PubMed ID: 18404780
[TBL] [Abstract][Full Text] [Related]
10. Emerging drugs for treatment of anemia of chronic kidney disease.
Magwood JS; Lebby A; Chen B; Kessler S; Norris L; Bennett CL
Expert Opin Emerg Drugs; 2013 Dec; 18(4):421-9. PubMed ID: 24033253
[TBL] [Abstract][Full Text] [Related]
11. Erythroid-stimulating agents in cancer therapy: potential dangers and biologic mechanisms.
Hadland BK; Longmore GD
J Clin Oncol; 2009 Sep; 27(25):4217-26. PubMed ID: 19636005
[TBL] [Abstract][Full Text] [Related]
12. The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia.
Landau D; London L; Bandach I; Segev Y
PLoS One; 2018; 13(5):e0196684. PubMed ID: 29738538
[TBL] [Abstract][Full Text] [Related]
13. Anemia Management in the Cancer Patient With CKD and End-Stage Kidney Disease.
Rashidi A; Garimella PS; Al-Asaad A; Kharadjian T; Torres MN; Thakkar J
Adv Chronic Kidney Dis; 2022 Mar; 29(2):180-187.e1. PubMed ID: 35817525
[TBL] [Abstract][Full Text] [Related]
14. Down-Regulation of Cardiac Erythropoietin Receptor and its Downstream Activated Signal Transducer Phospho-STAT-5 in a Rat Model of Chronic Kidney Disease.
Hertzberg-Bigelman E; Barashi R; Levy R; Cohen L; Ben-Shoshan J; Keren G; Entin-Meer M
Isr Med Assoc J; 2016 Jun; 18(6):326-30. PubMed ID: 27468524
[TBL] [Abstract][Full Text] [Related]
15. Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells.
Bennett CL; Lai SY; Sartor O; Georgantopoulos P; Hrushesky WJ; Henke M; Armitage JO
JAMA Oncol; 2016 Jan; 2(1):134-6. PubMed ID: 26606114
[No Abstract] [Full Text] [Related]
16. Erythropoietin in cancer patients.
Glaspy JA
Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468
[TBL] [Abstract][Full Text] [Related]
17. Erythropoietin resistance contributes to anaemia in chronic heart failure and relates to aberrant JAK-STAT signal transduction.
Okonko DO; Marley SB; Anker SD; Poole-Wilson PA; Gordon MY
Int J Cardiol; 2013 Apr; 164(3):359-64. PubMed ID: 21821297
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin in cancer patients: pros and cons.
Dicato M; Plawny L
Curr Opin Oncol; 2010 Jul; 22(4):307-11. PubMed ID: 20498598
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin and its receptor in breast cancer: putting together the pieces of the puzzle.
Mannello F; Tonti GA
Oncologist; 2008 Jul; 13(7):761-8. PubMed ID: 18596367
[TBL] [Abstract][Full Text] [Related]
20. [Treatment anaemia of chronic kidney disease in predialysis patients (stage 1-4)].
Lovcić V; Vujić J; Ivanac Janković R; Basić-Jukić N; Barisić I; Lovcić P; Dzapo M
Acta Med Croatica; 2009 Sep; 63 Suppl 1():11-6. PubMed ID: 20232547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
